|
|
CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.
Number of employees : 304 people.
|
|
|
| 2018 | 2019 | Delta | | USD (in Million) | % | USD (in Million) | % | | Clustered Regularly Interspaced Short Palindromic Repeats - Associated Protein 9 | 3.12 | 100% | 289.59 | 100% | +9169.85% |
|
|
|
| 2018 | 2019 | Delta | | USD (in Million) | % | USD (in Million) | % | | Switzerland & United States | 3.12 | 100% | 289.59 | 100% | +9169.85% |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
70,847,745 |
60,848,959 |
85.9% |
195,316 |
0.3% |
85.9% |
|
|
|
| Name | Equities | % | | ARK Investment Management LLC | 8,457,320 |
12.0% | | Capital Research & Management Co. (International Investors) | 7,519,803 |
10.6% | | Nikko Asset Management Americas, Inc. | 3,697,667 |
5.23% | | Versant Venture Management LLC | 3,324,499 |
4.71% | | GlaxoSmithKline plc | 3,220,627 |
4.56% | | Bayer Aktiengesellschaft | 2,954,775 |
4.18% | | Vertex Pharmaceuticals Incorporated | 2,690,470 |
3.81% | | Capital Research & Management Co. (Global Investors) | 1,931,930 |
2.73% | | NEA Management Co. LLC | 1,590,002 |
2.25% | | T. Rowe Price Associates, Inc. (Investment Management) | 1,375,327 |
1.95% |
|
| Company contact information |
|
|
|
|
Sector Biotechnology & Medical Research - NEC
| | 1st jan. | Capitalization (M$) |
 |
 | CRISPR THERAPEUTICS AG | 99.57% | 8 588 |
| | | |
|
| IQVIA HOLDINGS INC. | 9.26% | 32 365 |
 | HANGZHOU TIGERMED CONSULTING CO.,LTD | 79.46% | 15 070 |
| PRA HEALTH SCIENCES, INC. | -0.14% | 7 120 |
| SYNEOS HEALTH, INC. | 12.08% | 6 932 |
| NOVAVAX, INC. | 2,477.89% | 6 427 |
| FIBROGEN, INC. | -6.34% | 3 656 |
 | TAKARA BIO INC. | 43.36% | 3 425 |
| ALKERMES PLC | -9.31% | 2 944 |
| REVOLUTION MEDICINES, INC. | 0.00% | 2 919 |
| REPLIMUNE GROUP, INC. | 261.18% | 2 382 |
| INTELLIA THERAPEUTICS, INC. | 168.44% | 2 327 |
| EDITAS MEDICINE, INC. | 5.84% | 1 938 |
| PHATHOM PHARMACEUTICALS, INC. | 38.50% | 1 118 |
 | CELLECTIS | 25.38% | 999 |
| TCR2 THERAPEUTICS INC. | 92.58% | 918 |
| CARDIFF ONCOLOGY, INC. | 1,667.74% | 774 |
 | BASILEA PHARMACEUTICA AG | 16.30% | 651 |
| GOSSAMER BIO, INC. | -42.55% | 641 |
| OYSTER POINT PHARMA, INC. | -12.03% | 556 |
| INNATE PHARMA | -22.32% | 437 |
Connections : CRISPR Therapeutics AG |
Canada
Deutschland
France
Schweiz (DE)
United Kingdom
Report
